logo_tight_cut_2000.png
PRESS RELEASE: Redeye’s initiating research coverage on SSH.COM has been published
June 23, 2021 11:13 ET | SSH Communications Security Corporation
Redeye’s initiating research coverage on SSH.COM has been published Helsinki, Finland – June 23rd, 2021 – As announced on April 7th, 2021 the technology sector-focused Swedish investment bank Redeye...
Marble Arch Research, Inc. Initiates Research Coverage of Healixa Inc.
May 17, 2021 09:56 ET | Emerald Organic Products Inc.
Holbrook, New York, May 17, 2021 (GLOBE NEWSWIRE) -- Healixa, Inc. (OTC Pink: EMOR) (“Healixa”, or the “Company”), a healthcare technology company delivering seamless and instant virtual care from...
PRESS RELEASE: Swedish investment bank Redeye to start coverage of SSH.COM
April 07, 2021 05:00 ET | SSH Communications Security Corporation
SSH aims to further improve the transparency of its businessand increase the profile of SSH among investors Helsinki – April 7, 2021 – SSH.COM has signed an agreement with the technology...
LEHDISTÖTIEDOTE: Ruotsalainen investointipankki Redeye aloittaa SSH.COM:in seurannan
April 07, 2021 05:00 ET | SSH Communications Security Oyj
SSH:n tavoite on parantaa entisestään liiketoiminnan läpinäkyvyyttäja lisätä SSH:n tunnettuutta sijoittajien keskuudessa Helsinki – 07.04.2021 – SSH.COM on solminut ruotsalaisen teknologiayrityksiin...
Maxim Group & H.C. Wainwright Analysts Confirm Co-Diagnostics (NADSAQ:CODX) Buy Rating with PTs of $20 and $29
November 24, 2020 08:00 ET | BDA International
New York City, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The global upsurge in COVID-19 has kept testing and Co-Diagnostics (NASDAQ: CODX) under the analysts’ microscope.  Within its client circular, the...
Saliva-Based Test Powered by Co-Diagnostics (NASDAQ:CODX) a Game Changer
August 05, 2020 07:30 ET | BDA International
New York City, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Saliva-Based Test Powered by Co-Diagnostics (NASDAQ:CODX) a Game Changer  Maxim reiterate Buy with a price target of $30 Earlier this week,...
H.C. Wainwright reiterates ‘Buy’ for Co-Diagnostics (NASDAQ:CODX) with a $35 Price Target as COVID-19 Surge Boosts Testing Demand
July 14, 2020 07:30 ET | BDA International
New York City, July 14, 2020 (GLOBE NEWSWIRE) -- Analyst Yi Chen of H.C. Wainwright & Co. reiterated his ‘buy’ coverage on Co-Diagnostics (NASDAQ:CODX), the Utah-based molecular diagnostics...
Co-Diagnostics (NASDAQ:CODX) Analysts Set Price Target Between $30 and $36
May 28, 2020 09:00 ET | BDA International
New York City, May 28, 2020 (GLOBE NEWSWIRE) -- Analysts from H.C. Wainwright, Maxim Group and Litchfield Hills have all upgraded or reiterated Co-Diagnostics (NASDAQ: CODX) as “Buy” rating in the...
Co-Diagnostics (NASDAQ:CODX) Reiterated Buy; Joins Distinguished Group Racing to Meet Unprecedented Global Demand for COVID-19 Testing
March 25, 2020 11:30 ET | BDA International
NEW YORK CITY, March 25, 2020 (GLOBE NEWSWIRE) -- The global shortage of COVID-19 testing kits is hitting the United States and other nations hard, but a recent FDA policy change means that...
Buy for Co-Diagnostics (NASDAQ:CODX) Reiterated by H.C. Wainwright with $20 Price Target
March 11, 2020 09:30 ET | BDA International
New York City, March 11, 2020 (GLOBE NEWSWIRE) -- Analyst Yi Chen released additional coverage on Co-Diagnostics (NASDAQ:CODX), a Utah-based molecular diagnostics company, raising the firm’s price...